Dupixent Stock Market Invest

Positive Results for Dupixent in Phase 3 Study for CSU Patients Sep 12, 2024

Dupixent® (dupilumab) Becomes First Targeted Therapy in EU for COPD Patients with Elevated Eosinophils Jul 3, 2024

FDA Prioritizes Review of Dupixent for COPD with Type 2 Inflammation, a Potential Breakthrough by Regeneron and Sanofi Jun 1, 2024